Systemic anticancer therapy in the last 30 days of life: Retrospective audit from an Australian Regional Cancer Centre

Abstract

Background

Cessation of chemotherapy at an appropriate time is an important component of good quality palliative care. Published studies looking at administration of chemotherapy at the end of life vary widely.

Objective

To retrospectively determine the rate of death occurring within 14 and 30 days of chemotherapy and use this to benchmark against other cancer centres as a quality of care measure.

Method

All adult patients who received systemic anticancer therapy for solid tumours and haematological malignancies at an Australian Regional Cancer Centre between 2011 and 2015 were included.

Results

Over a five-year period, 1215 patients received systemic anticancer therapy. Of these, 23 (1.89%) died within 14 days following systemic anticancer therapy and 68 (5.60%) within 30 days. All patients who died had been treated with palliative intent. Mean time to death was 17.7 days. The majority were female (61.8%) and the mean age was 62.3 years. The most common cause of death was disease progression (80.9%). Nearly half died at the Regional Cancer Centre, including 30.9% who lived in rural or remote localities.

Conclusion

The rate of death observed in this study is at the lower end of the range seen in published studies for both the last 14 and 30 days post-systemic anticancer therapy. It is important to routinely collect data to enable benchmarking against other institutions, determine factors potentially associated with higher risks of mortality at the end of life and improve clinical decision making.

Keywords

Benchmark cancer patients chemotherapy death end of life

Get full access to this article

View all access options for this article.

References

Earle

Park

Lai

et al.

Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 2003; 21: 1133–1138.

Earle

Neville

Landrum et al.

Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care 2005; 17: 505–509.

O’Brien

MER

Borthwick

Rigg

et al.

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br J Cancer 2006; 95: 1632–1636.

Murillo

Koeller

. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006; 11: 1095–1099.

Braga

Miranda

Fonseca

et al.

The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychooncology 2007; 16: 863–868.

Yun

Kwak

Park

et al.

Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 2007; 72: 164–171.

Martoni

Tanneberger

Mutri

. Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 2007; 93: 417–422.

Keam

Lee

et al.

Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol 2008; 38: 381–386.

Goncalves

Goyanes

. Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer 2008; 16: 321–327.

10.

Kao

Shafiq

Vardy

et al.

Use of chemotherapy at the end of life in oncology patients. Ann Oncol 2009; 20: 1555–1559.

11.

Hashimoto

Yonemori

Katsumata

et al.

Factors that affect the duration of the interval between completion of palliative chemotherapy and death. Oncologist 2009; 14: 752–759.

12.

Nappa

Lindqvist

Rasmussen

et al.

Palliative chemotherapy during the last month of life. Ann Oncol 2011; 11: 2375–2380.

13.

Yoong

Seah

Hamilton

et al.

Mortality within 30 days of receiving systemic anti-cancer therapy at a regional oncology unit: what have we learned?

Asia Pac J Clin Oncol 2012; 8: 325–329.

14.

Soh

TIP

Yuen

Teo

et al.

Targeted therapy at the end of life in advanced cancer patients. J Palliat Med 2012; 15: 991–997.

15.

Randen

Helde-Frankling

Runesdotter

et al.

Treatment decisions and discontinuation of chemotherapy near the end-of-life, in relation to socioeconomic variables. Acta Oncol 2013; 52: 1062–1066.

16.

Zdenkowski

Cavenagh

et al.

Administration of chemotherapy with palliative intent in the last 30 days of life: the balance between palliation and chemotherapy. Intern Med J 2013; 43: 1191–1198.

17.

Khoja

McGurk

O’Hara

et al.

Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre. Eur J Cancer 2015; 51: 233–240.

18.

Pacetti

Paganini

Orlandi

et al.

Chemotherapy in the last 30 days of life of advanced cancer patients. Support Care Cancer 2015; 23: 3277–3280.

19.

Assi

Rassy

Tabchi

et al.

Treatment of cancer patients in their last month of life: aimless chemotherapy. Support Care Cancer 2016; 24: 1603–1608.

20.

Emanuel

Young-Xu

Levinsky

et al.

Chemotherapy use among medicare beneficiaries at the end of life. Ann Intern Med 2003; 138: 639–643.

21.

Earle

Neville

Landrum

et al.

Trends in the aggressiveness in cancer care near the end of life. J Clin Oncol 2004; 22: 315–321.

22.

Barbera

Paszat

Chartier

. Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care 2006; 22: 12–17.

23.

Wallingham

Saxon

Bomb

et al.

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol 2016; 17: 1203–1216.

24.

Prigerson

Bao

Shah

et al.

Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 2015; 1: 778–784.

25.

Harrington

Smith

. The role of chemotherapy at the end of life: “When is enough, enough?”. JAMA 2008; 299: 2667–2678.

26.

Chan

Lam

Siu

et al.

Chemotherapy at end-of-life: an integration of oncology and palliative team. Support Care Cancer 2016; 24: 1421–1427.

27.

Braga

. Why do our patients get chemotherapy until the end of life? Ann Oncol 2011; 22: 2345–2348.

28.

Rocque

Cleary

. Palliative care reduces morbidity and mortality in cancer. Nat Rev Clin Oncol 2013; 10: 80–89.

29.

Greer

Pirl

Jackson

et al.

Effective of palliative care on chemotherapy use in end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 2012; 30: 394–400.